Dan Vlad Iosifescu MD
Professor of Psychiatry, NYU School of Medicine and Director, Clinical Research Division, Nathan Kline Institute
Join to View Full Profile
1 Park AveFl 8New York, NY 10016
Phone+1 212-263-7419
Dr. Iosifescu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Dan Iosifescu is a psychiatrist based in New York, NY, with a robust academic and clinical background. He completed his medical education at Carol Davila University of Medicine and Pharmacy, a residency in psychiatry at Massachusetts General Hospital and McLean Hospital, and further training with a Master of Medical Science in Clinical Investigation at Harvard Medical School and MIT. He is currently a Professor of Psychiatry at New York University School of Medicine and the Deputy Director of the Nathan Kline Institute for Psychiatric Research. His clinical expertise encompasses difficult to treat mood disorders (depression and bipolar disorder).
Dr. Iosifescu has a significant background in clinical research, including leading multi-center clinical trials and authoring numerous publications in top-tier medical journals. His research is focused on novel pharmacological treatments (such as ketamine, dextromethorphan combinations, and other glutamatergic drugs) and devices (such as photobiomodulation with near infrared light and novel forms of magnetic stimulation) for patients with severe mood and cognitive disorders. His research uses neuroimaging (MRI, MRS, PET), neuropsychological tests and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities in mood and cognitive disorders and their impact on clinical treatment.
Education & Training
Harvard Medical School and Massachusetts Institute of TechnologyMaster of Medical Science (M.M.Sc.), Clinical Investigation, 2001 - 2003
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2000- Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 1996 - 1997
Carol Davila University of Medicine and PharmacyClass of 1992
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1998 - 2027
NY State Medical License 2009 - 2027
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression Start of enrollment: 2003 Apr 01
- Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder
- Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram Start of enrollment: 2003 Jul 01
Publications & Presentations
PubMed
- Comparative diagnostic accuracy of panic provocation tests: A meta-analysis.Umit Tural, Sara Rose Shannon, Dan V Iosifescu
Journal of Psychiatric Research. 2026-09-01 - Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders.David T Liebers, Tianshe He, Rebecca A Betensky, Chunlei Zheng, Kaitlin N Swinnerton
JAMA Network Open. 2026-06-01 - Decisional reference point pathology: A cognitive mechanism for and a correlate of major depressive disorder in humans.Aadith Vittala, Lulu Wu, Dongni Yan, David Liebers, Elizabeth Tell
Proceedings of the National Academy of Sciences of the United States of America. 2026-05-26
Journal Articles
- Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients with Major Depressive DisorderKatherine A Collins, Dan V Iosifescu, James W Murrough, Eric J Nestler, Nisha Chadha, Nature
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Authored Content
- Dopamine Release in Antidepressant-Naïve Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging StudyMay 2018
- Dopamine Release in Antidepressant-Naïve Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging StudyMay 2018
- F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
Press Mentions
Axsome Therapeutics Receives FDA Nod for AuvelitySeptember 7th, 2022- FDA Approves First Fast-Acting Oral Drug for Clinical Depression That Works in 1 WeekAugust 25th, 2022
- Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder?July 12th, 2022
Grant Support
- Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2026
- Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2026
- Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025
- Efficacy And Safety Of Galantamine For Dysfunction In Bipolar DisorderNational Institute Of Mental Health2010–2011
- Efficacy And Safety Of Galantamine For Dysfunction In Bipolar DisorderNational Institute Of Mental Health2008–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
